We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · August 09, 2021

Long-Term Safety and Efficacy of Subretinal Gene Therapy for CNGA3–Associated Achromatopsia

The British Journal of Ophthalmology


Additional Info

The British Journal of Ophthalmology
Three-Year Results of Phase 1 Retinal Gene Therapy Trial for CNGA3-Mutated Achromatopsia: Results of a Non-Randomised Controlled Trial
Br J Ophthalmol 2021 May 18;[EPub Ahead of Print], FF Reichel, S Michalakis, B Wilhelm, D Zobor, R Muehlfriedel, S Kohl, N Weisschuh, V Sothilingam, L Kuehlewein, N Kahle, I Seitz, F Paquet-Durand, SH Tsang, P Martus, T Peters, M Seeliger, KU Bartz-Schmidt, M Ueffing, E Zrenner, M Biel, B Wissinger, D Fischer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading